IDEAYA Enters License Deal With Hengrui Pharma To Develop SHR-4849 Worldwide Outside Of GreaterChina
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced that it has entered into exclusive license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program.
:max_bytes(150000):strip_icc():format(jpeg)/buy-a-car-online-38990fbe8d804ac1bb26de361a5710b2.jpeg "How to Buy a Car Online")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1966125172-2a80f72013bb40568059b3b80261ae0d.jpg "How To Use Artificial Intelligence To Invest")
:max_bytes(150000):strip_icc():format(jpeg)/Unhappywomanlooksatbillswithcomputer-e586960d99e84bfba87192404f0c88ff.jpeg "How to Get Debt Relief")